利福布汀与黏菌素联合用药可降低治疗鲍曼不动杆菌时耐药性的产生。
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii.
机构信息
Department of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Los Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA.
出版信息
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02204-20.
Recently, we reported rifabutin hyperactivity against We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic and , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant infections.
最近，我们报道了利福布汀对 的活性。我们试图描述利福布汀和多粘菌素之间潜在的相互作用，多粘菌素是治疗碳青霉烯类耐药感染的最后手段。利福布汀和多粘菌素具有协同作用，并且低剂量多粘菌素能显著抑制利福布汀耐药性的产生。因此，这种联合治疗是治疗高度耐药 感染的一种有前途的治疗选择。
Zotero 插件